Femasys stock.

ATLANTA, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office ...

Femasys stock. Things To Know About Femasys stock.

Femasys Inc (NASDAQ: FEMY) shares surged after the company received FDA 510(k) clearance for FemaSeed, an infertility treatment designed to deliver sperm directly to where conception occurs in a https://www.femasys.com. Femasys Inc., a biomedical company, develops novel solutions for women's healthcare market in the United States and internationally. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine ...Femasys GAAP EPS of -$0.22 misses by $0.02, revenue of $0.32M misses by $0.05M SA News Thu, Aug. 10 Femsys stock jumps 21% after FDA green lights FemBloc testingUnder the terms of the investment, the investors were also issued two series of warrants: warrants to purchase approximately 5.8 million shares of common stock at an exercise price of $1.18 per share expiring one year from issuance and warrants to purchase approximately 5.8 million shares of common stock at an exercise price of $1.475 per …The Femasys Inc. stock price fell by -3.27% on the last day (Wednesday, 29th Nov 2023) from $1.01 to $0.98. During the last trading day the stock fluctuated 6.91% from a day low at $0.96 to a day high of $1.03. The price has fallen in 5 of the last 10 days but is still up by 5.05% over the past 2 weeks.

According to 3 stock analysts, the average 12-month stock price forecast for Femasys stock is $9.00, which predicts an increase of 845.18%. The lowest target is $7.00 and the highest is $10. On average, analysts rate Femasys stock as a strong buy.Electronic Technology. Industry. Electronic Equipment/Instruments. No executives to display. Corporate headquarters. --, --. Find real-time FEMY - Femasys Inc stock quotes, company profile, news ...

Comparatively, 16.4% of Femasys shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Earnings & Valuation. This table compares Beyond Air and Femasys’ revenue, earnings per share …The past week has seen Femasys Inc. (FEMY), a company known for its work in the healthcare sector, experience fluctuations in its stock price. With a 52-week range of $0.2480 - $4.7500 and an average volume of 14,323,125, the stock's performance has been intriguing. Photo by Afif Ramdhasuma on Unsplash. Factors driving this week's …

Nov 30, 2023 · Why Is Femasys (FEMY) Stock Up 181% Today? investorplace.com - September 26 at 9:11 AM. Femasys up 205% as FDA clears fertility treatment. seekingalpha.com - September 25 at 11:56 PM. Femasys Secures FDA 510 (k) Clearance To Market FemaSeed. markets.businessinsider.com - September 25 at 6:56 PM. Shares of biomedical firm Femasys soared on Thursday.; Management announced the issuance of a notice of allowance for its patent application. FEMY stock soared on IP protection of its first-of-its ...Read Full Company Summary for FEMY here. View Femasys Inc FEMY investment & stock information. Get the latest Femasys Inc FEMY detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.In addition, Femasys has granted the underwriters a 30-day option to purchase an additional 397,500 shares of its common stock at the initial public offering price, less the underwriting discounts ...FEMY | Complete Femasys Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Femasys Inc (NASDAQ:FEMY) trade information. Femasys Inc (FEMY) registered a -2.33% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.33% in intraday trading to $0.93 this Friday, 12/01/23, hitting a weekly high. The stock’s 5-day price performance is -9.71%, and it has moved …

Femasys was previously notified by Nasdaq on June 1, 2023 that it was not in compliance with the minimum bid price rule (“the Rule”) because its common stock failed to meet the closing bid ...

- FemaSeed ® is the first-ever, first-line approach designed to deliver sperm directly where conception occurs -. ATLANTA, April 18, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs by developing a suite of products and product candidates that include minimally invasive, in-office technologies for reproductive health, today announced the ...Femasys : Corporate Presentation June 2023. Disrupting Convention in Women's Health Through Continuous Innovation. This Presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not limited to current ...Share this article. Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer -- Thought leader from top-ranked academic gynecology …WebOct 11, 2023 · Femasys was previously notified by Nasdaq on June 1, 2023 that it was not in compliance with the minimum bid price rule (“the Rule”) because its common stock failed to meet the closing bid ... The stock is up ~205% in after-hours trading on Monday. Femasys (FEMY) says that FeedSeed is "less invasive and more affordable than assisted reproduction procedures, such as in vitro ...Operating Status Active. Last Funding Type Post-IPO Debt. Legal Name Femasys Inc. Stock Symbol NASDAQ:FEMY. Company Type For Profit. Contact Email [email protected]. Phone Number 1 (770) 500-3910. Femasys is a biomedical company focused on transforming women’s healthcare worldwide by …

Find the latest Femasys Inc. (FEMY) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Femasys was previously notified by Nasdaq on June 1, 2023 that it was not in compliance with the minimum bid price rule (“the Rule”) because its common stock failed to meet the closing bid ...Get the latest Femasys Inc (FEMY) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Femasys saw a decline in short interest in November. As of November 15th, there was short interest totaling 286,700 shares, a decline of 33.0% from the previous total of 427,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will ...Find the latest Femasys Inc. (FEMY) stock quote, history, news and other vital information to help you with your stock trading and investing.

Femasys Inc. (NASDAQ: FEMY) shares fell lower on Wednesday, a pullback from Tuesday's surge in price following the announcement that the company received FDA 510(k) clearance for FemaSeed, 

That’s a massive surge in trading volume compared to Femasys’ daily average of about 3.3 million shares. FEMY stock is up 180.9% as of Tuesday morning after closing out Monday down 63.2% year ...Femasys Inc (FEMY) has experienced a 3.06% rise in stock performance for the past week, with a -36.36% drop in the past month, and a 113.56% rise in the past quarter. The volatility ratio for the week is 11.20%, and the volatility levels for the past 30 days are at 13.36% for FEMY.The ratio of current share price to trailing twelve month EPS that signals if the price is high or low compared to other stocks Dividend yield The ratio of annual dividend to current …WebNov 30, 2023 · ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office ... Gainers Innovative Eyewear, Inc. (NASDAQ: LUCY) jumped 108% to $3.3943 on abnormally-high volume. The company released its October investor presentation yesterday.Health Canada approved Femasys' ( NASDAQ: FEMY) FemaSeed, a product for localized directional insemination for infertility. The company said FemaSeed is the first-ever infertility solution aimed ...Why Is Femasys (FEMY) Stock Up 181% Today? investorplace.com - September 26 at 9:11 AM. Femasys up 205% as FDA clears fertility treatment. seekingalpha.com - September 25 at 11:56 PM. Femasys Secures FDA 510 (k) Clearance To Market FemaSeed. markets.businessinsider.com - September 25 at 6:56 PM.

Our Mission. Femasys is a biomedical company focused on meeting women’s unmet needs worldwide by developing a broad portfolio of innovative product candidates and products that include minimally invasive, in-office technologies for reproductive health.

If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.

Oct 2, 2023 · Femasys Inc, a medical technology company, has been attracting attention from investors due to its positive stock performance on October 2, 2023. According to data from CNN Money, the company has received favorable price forecasts from four analysts, with a median target of $8.50. The high estimate is $13.00, while the low estimate is $5.00. Femasys Inc. Watch NEW Set a price target alert After Hours Last Updated: Nov 27, 2023 5:01 p.m. EST Delayed quote $ 1.0500 0.02 1.94% After Hours Volume: 21.5K Advanced Charting Volume: 842.8K... https://www.femasys.com. Femasys Inc., a biomedical company, develops novel solutions for women's healthcare market in the United States and internationally. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine ...Oct 2, 2023 · What To Know: HC Wainwright & Co. analyst Emily Bodnar maintained Femasys with a Buy rating and raised the price target from $5 to $13 on Friday. Femasys also announced last week that it has ... Femasys Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023. Nov. 14. CI. Earnings Flash (FEMY) FEMASYS Reports Q3 Revenue $86,186. Nov. 14. MT. Femasys Inc. announced that it expects to receive $6.85 million in funding from PharmaCyte Biotech, Inc. Nov. 13.HC Wainwright & Co. analyst Emily Bodnar maintained Femasys with a Buy rating and raised the price target from $5 to $13 on Friday. Femasys also announced last week that it has activated enrollment for its FemBloc trial to investigate a permanent birth control candidate. Shares of FEMY are moving higher on very heavy trading volume.Nov 30, 2023 · ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced the ... Description. Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient ...

Discover historical prices for FEMY stock on Yahoo Finance. View daily, weekly or monthly format back to when Femasys Inc. stock was issued. ... Femasys Inc. (FEMY) NasdaqCM - NasdaqCM Real Time ... Nov 24, 2023 · Complete Femasys Inc. stock information by Barron's. View real-time FEMY stock price and news, along with industry-best analysis. Overview. Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health.Instagram:https://instagram. forex auto tradingbest day trader accountsbest mortgage company orlandorisky stocks to invest in FEMY Stock 12 Months Forecast. Based on 4 Wall Street analysts offering 12 month price targets for Femasys in the last 3 months. The average price target is $10.67 with a high forecast of $13.00 and a low forecast of $7.00. The average price target represents a 620.95% change from the last price of $1.48. reit to buyblackrock crypto Femasys Inc (NASDAQ: FEMY) shares surged after the company received FDA 510(k) clearance for FemaSeed, an infertility treatment designed to deliver sperm directly to where conception occurs in a  5 stocks under 5 Jul 27, 2023 · FemBloc® patent application provides additional coverage for Femasys’ therapeutic option for women seeking permanent birth controlATLANTA, July 27, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ ... Femasys Inc. Watch NEW Set a price target alert After Hours Last Updated: Nov 27, 2023 5:01 p.m. EST Delayed quote $ 1.0500 0.02 1.94% After Hours Volume: 21.5K Advanced …Web